Sage Therapeutics (SAGE) Scheduled to Post Quarterly Earnings on Thursday

Sage Therapeutics (NASDAQ:SAGE) is set to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.73. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company had revenue of $77.97 million during the quarter, compared to the consensus estimate of $60.15 million. During the same quarter in the prior year, the company earned ($2.47) EPS. The firm’s quarterly revenue was up 2621.5% compared to the same quarter last year. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Sage Therapeutics Stock Performance

Shares of Sage Therapeutics stock opened at $12.89 on Tuesday. Sage Therapeutics has a 52-week low of $10.92 and a 52-week high of $59.99. The stock’s 50-day simple moving average is $19.42 and its 200 day simple moving average is $20.82.

Wall Street Analysts Forecast Growth

SAGE has been the topic of several research reports. Morgan Stanley boosted their price target on shares of Sage Therapeutics from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. TD Cowen lowered their target price on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Wedbush reaffirmed a “neutral” rating and issued a $24.00 price target on shares of Sage Therapeutics in a report on Wednesday, April 17th. StockNews.com lowered Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Royal Bank of Canada increased their price objective on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a report on Thursday, February 15th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $39.28.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.